GW Pharmaceuticals PLC- (GWPH) Upgraded by BidaskClub to Hold

BidaskClub upgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Several other analysts also recently weighed in on the company. Cantor Fitzgerald set a $235.00 target price on GW Pharmaceuticals PLC- and gave the company a buy rating in a research note on Thursday, July 12th. ValuEngine downgraded GW Pharmaceuticals PLC- from a buy rating to a hold rating in a research note on Thursday, August 2nd. Bank of America boosted their price objective on GW Pharmaceuticals PLC- from $170.00 to $200.00 and gave the stock a buy rating in a research note on Tuesday, June 26th. Zacks Investment Research raised GW Pharmaceuticals PLC- from a hold rating to a buy rating and set a $148.00 price objective on the stock in a research note on Tuesday, April 24th. Finally, Cowen reissued a buy rating and issued a $165.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, May 9th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $175.29.

GW Pharmaceuticals PLC- traded down $0.96, hitting $134.96, during mid-day trading on Friday, Marketbeat.com reports. 207,860 shares of the company’s stock traded hands, compared to its average volume of 339,874. The company has a quick ratio of 11.22, a current ratio of 8.67 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a one year low of $96.42 and a one year high of $164.76.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating the consensus estimate of ($2.40) by $1.14. The firm had revenue of $3.46 million for the quarter, compared to the consensus estimate of $2.00 million. GW Pharmaceuticals PLC- had a negative return on equity of 47.65% and a negative net margin of 1,392.61%. analysts predict that GW Pharmaceuticals PLC- will post -9.02 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Rothschild Investment Corp IL raised its stake in shares of GW Pharmaceuticals PLC- by 70.5% in the 2nd quarter. Rothschild Investment Corp IL now owns 20,332 shares of the biopharmaceutical company’s stock worth $2,837,000 after buying an additional 8,405 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter worth $481,000. Wells Fargo & Company MN raised its stake in shares of GW Pharmaceuticals PLC- by 20.6% in the 1st quarter. Wells Fargo & Company MN now owns 29,172 shares of the biopharmaceutical company’s stock worth $3,288,000 after buying an additional 4,987 shares in the last quarter. RFG Advisory Group LLC bought a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter worth $410,000. Finally, LPL Financial LLC grew its holdings in shares of GW Pharmaceuticals PLC- by 9.0% in the 1st quarter. LPL Financial LLC now owns 8,418 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 692 shares during the last quarter. 72.78% of the stock is currently owned by institutional investors.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Further Reading: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply